Logo

BridgeBio Pharma Partners with Kyowa Kirin to Develop and Commercialize Infigratinib to Treat Skeletal Dysplasias in Japan

Share this
BridgeBio Pharma

BridgeBio Pharma Partners with Kyowa Kirin to Develop and Commercialize Infigratinib to Treat Skeletal Dysplasias in Japan

Shots:

  • Kyowa Kirin signed an agreement with BridgeBio’s affiliate, QED Therapeutics under which, Kyowa Kirin received an exclusive license to develop & commercialize infigratinib to treat ACH, hypochondroplasia & other skeletal dysplasias across Japan
  • As per the agreement, BridgeBio will receive an up front payment of $100M & is eligible to receive potential milestone-based payments, plus high-twenties percent royalties
  • Infigratinib (small molecule FGFR3 inhibitor) is currently being evaluated in a P-III (PROPEL 3) clinical trial for safety & efficacy among children & adolescents with ACH. Additionally, BridgeBio also expects to initiate an observational study (ACCEL) evaluating infigratinib in hypochondroplasia by H1’24

Ref: BridgeBio | Image: BridgeBio

Related News:- Kyowa Kirin to Acquire Orchard Therapeutics for ~$477.6M

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions